Drugs / Fluad
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06015282 Comparator | Nov 2023 → Mar 2024 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluad | “Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO...” NCT06015282 ↗ |
| Known as | aQIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015282 ↗ |
| Modality | Vaccine | “Adjuvanted, egg-derived Quadrivalent Influenza Vaccine” NCT06015282 ↗ |